As many as one-fifth of patients hospitalized with severe COVID-19 in the U.S. who may have benefitted from treatment with dexamethasone or closely related drugs were not given such treatment at the height of the pandemic.
Drug safety and effectiveness, pharmaceutical pricing and policy, antibiotics and antimicrobial resistance, and more
Joshua Sharfstein, MD, works to develop and promote public health strategies, healthcare payment approaches, and regulatory policies that advance health and equity.
G. Caleb Alexander, MD, MS, is a practicing internist and epidemiologist focused on maximizing the use, safety, and effectiveness of prescription medicines.
Gerard Anderson, PhD, works with policymakers to control health care spending.
Aditi Sen, PhD, MA, is a health economist working to design and implement payment and delivery systems that improve quality of and access to care for all Americans.